IGC Stock Overview
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
IGC Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.51 |
52 Week High | US$0.91 |
52 Week Low | US$0.25 |
Beta | 1.77 |
1 Month Change | 6.72% |
3 Month Change | 76.39% |
1 Year Change | 53.01% |
3 Year Change | -67.44% |
5 Year Change | -61.22% |
Change since IPO | -99.08% |
Recent News & Updates
Shareholder Returns
IGC | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 15.7% | 1.0% | -0.7% |
1Y | 53.0% | 11.6% | 22.3% |
Return vs Industry: IGC exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: IGC exceeded the US Market which returned 22.3% over the past year.
Price Volatility
IGC volatility | |
---|---|
IGC Average Weekly Movement | 17.3% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IGC's share price has been volatile over the past 3 months.
Volatility Over Time: IGC's weekly volatility has increased from 11% to 17% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 61 | Ram Mukunda | igcpharma.com |
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps.
IGC Pharma, Inc. Fundamentals Summary
IGC fundamental statistics | |
---|---|
Market cap | US$35.81m |
Earnings (TTM) | -US$14.14m |
Revenue (TTM) | US$1.22m |
27.6x
P/S Ratio-2.4x
P/E RatioIs IGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IGC income statement (TTM) | |
---|---|
Revenue | US$1.22m |
Cost of Revenue | US$591.00k |
Gross Profit | US$625.00k |
Other Expenses | US$14.77m |
Earnings | -US$14.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.21 |
Gross Margin | 51.40% |
Net Profit Margin | -1,163.24% |
Debt/Equity Ratio | 1.6% |
How did IGC perform over the long term?
See historical performance and comparison